Oppenheimer Maintains Outperform on Corbus Pharmaceuticals, Raises Price Target to $51
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones has maintained an Outperform rating on Corbus Pharmaceuticals (NASDAQ:CRBP) and increased the price target from $20 to $51, indicating a positive outlook on the company's stock performance.
January 29, 2024 | 6:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Jeff Jones has reaffirmed Corbus Pharmaceuticals' Outperform rating and raised the price target from $20 to $51, suggesting a strong bullish stance on the stock.
The increase in price target by a reputable analyst typically signals a strong conviction in the company's future performance and growth potential. This can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100